London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think the China tie up went under the radar a bit.
https://www.lse.co.uk/rns/DNL/china-licencing-agreement-with-citrine-for-alkindi-qr9y06pqxl1wprh.html
I think news there could also be significant for the SP, although I do concede I am very fuzzy on likely progression re regulatory processes / timescales for this and whether existing data/trials can be used in their regulatory system.
But if Alkindi does achieve approval and sale in China then you would have to think that also bodes well for Chronocort.
China's vast population and increased focus on medical provision would present a substantial commercial opportunity for Diurnal.
FDA Special Protocol Assessment, I believe, is a pre-agreement on the design of the phase 3 trial. There seem to be advantages and disadvantages.
I don't believe the special protocol is in any way an accelerated approval and the timeline for the trial is still between 1 and 4 years, NEWS is due this month on the Special Protocol arrangement and perhaps this will include the timeline, is it possible the FDA may allow results from the EU trials?? I have no experience of this.
So, short term, IF the Special Protocol suggests a fast approval, this will benefit DNL in a number of ways;
- reduced cash burn (time waiting)
- closer to revenues in the US on Efmody
- positive news could well boost the share price
Chronocort (Efmody) failed previously in the US in 2018, since then, DNL has presented positive patient outcomes and of course EMA approval. So again, this may support a phase 3 trial at the faster end of the range.
ALB
Morning Scored,
I guess the question is "short term" or "long term", this placing is a no-win situation for private investors, it was all about giving the institutions a larger slice of the pie.
But from that point of view, the institutions are confident, and so confident that they are willing to pay a high price to acquire shares.
Shareholders are still valuing the company today at £99m, all things being equal, it will be worth £99m after the placing is complete. But there will be 30m new shares.
Long term, the prospects are fantastic, my question is can the management team deliver the pipeline ON TIME and WITHOUT further fund raising? Can the "adrenal franchise" start to fund future development?
Short term, there is little in the pipeline for approval until 2025; Efmody in the UK, there is Japan possibly, and Efmody in the US due 2025. UNLESS FDA Special Protocol Assessment changes this timeline - I am digging into this now.
ALB
BUY OR SELL whatever someone took the slack up - Watching close monday and ready to buy
It’s looking to bounce.
IF dnl drifts will add early 60/s risk reward great .Shame what happens here on open offers.I bought in last one at 60p went to 48 p .IM once bitten twice shy with shares . GLA all longs